Published in BMC Public Health on June 09, 2010
Abscess and self-treatment among injection drug users at four California syringe exchanges and their surrounding communities. Subst Use Misuse (2013) 0.89
Reducing the adverse impact of injection drug use in Canada. Can J Infect Dis Med Microbiol (2012) 0.80
A cross-sectional study describing factors associated with utilisation of GP services by a cohort of people who inject drugs. BMC Health Serv Res (2014) 0.80
Denial of pain medication by health care providers predicts in-hospital illicit drug use among individuals who use illicit drugs. Pain Res Manag (2015) 0.77
Antiretroviral Therapy (ART) Use, Human Immunodeficiency Virus (HIV)-1 RNA Suppression, and Medical Causes of Hospitalization Among HIV-Infected Intravenous Drug Users in the Late ART Era. Open Forum Infect Dis (2014) 0.77
Factors Associated with Leaving Hospital against Medical Advice among People Who Use Illicit Drugs in Vancouver, Canada. PLoS One (2015) 0.76
Willingness to access an in-hospital supervised injection facility among hospitalized people who use illicit drugs. J Hosp Med (2015) 0.75
Public Health and Public Order Outcomes Associated with Supervised Drug Consumption Facilities: a Systematic Review. Curr HIV/AIDS Rep (2017) 0.75
Self-report among injecting drug users: a review. Drug Alcohol Depend (1998) 9.16
Safer injection facility use and syringe sharing in injection drug users. Lancet (2005) 3.85
Hospital utilization and costs in a cohort of injection drug users. CMAJ (2001) 3.48
Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ (2004) 2.62
Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users. J Clin Epidemiol (1996) 2.18
High rates of primary care and emergency department use among injection drug users in Vancouver. J Public Health (Oxf) (2004) 1.95
Unstable housing, associated risk behaviour, and increased risk for HIV infection among injection drug users. Health Place (2004) 1.90
Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin Infect Dis (2001) 1.88
Soft tissue infections among injection drug users--San Francisco, California, 1996-2000. MMWR Morb Mortal Wkly Rep (2001) 1.86
Attendance at supervised injecting facilities and use of detoxification services. N Engl J Med (2006) 1.83
Bacterial infections in drug users. N Engl J Med (2005) 1.78
Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. Harm Reduct J (2004) 1.77
Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother (2004) 1.74
The social determinants of emergency department and hospital use by injection drug users in Canada. J Urban Health (1999) 1.67
Skin and soft tissue infections in injection drug users. Infect Dis Clin North Am (2002) 1.63
Care of injection drug users with soft tissue infections in San Francisco, California. Arch Surg (2002) 1.38
Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility. PLoS One (2008) 1.31
Right ventricular needle embolus in an injecting drug user: the need for early removal. Emerg Med J (2001) 1.31
Expanding harm reduction services through a wound and abscess clinic. Am J Public Health (2002) 1.24
Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infect Dis (2008) 1.23
Cutaneous complications of intravenous drug abuse. Br J Dermatol (2004) 1.20
Predictors of hospitalization for injection drug users seeking care for soft tissue infections. J Gen Intern Med (2007) 1.20
Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health (2008) 1.20
Non-fatal overdose among a cohort of active injection drug users recruited from a supervised injection facility. Am J Drug Alcohol Abuse (2008) 1.18
Accessing care for injection-related infections through a medically supervised injecting facility: a qualitative study. Drug Alcohol Depend (2008) 1.10
The groin hit: complications of intravenous drug abuse. Radiographics (1989) 1.08
Injection drug users: hospital care and charges. Drug Alcohol Depend (2001) 1.04
Drug users seeking emergency care for soft tissue infection at high risk for subsequent hospitalization and death. J Stud Alcohol Drugs (2008) 0.99
Bone and joint infections in injection drug users. Infect Dis Clin North Am (2002) 0.95
Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users. Ann Intern Med (1994) 0.95
Color coded duplex sonography of inguinal vessels in i.v. drug addicts. Vasa (2002) 0.85
Bacterial infections in HIV: the extent and nature of the problem. Int J STD AIDS (1997) 0.82
The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. CMAJ (2004) 21.24
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS (2003) 5.53
Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS (2002) 5.21
Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med (2002) 4.77
Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis (2004) 4.55
Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med (2003) 4.46
Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ (2003) 4.38
Social and structural violence and power relations in mitigating HIV risk of drug-using women in survival sex work. Soc Sci Med (2007) 4.14
Structural and environmental barriers to condom use negotiation with clients among female sex workers: implications for HIV-prevention strategies and policy. Am J Public Health (2009) 3.85
Safer injection facility use and syringe sharing in injection drug users. Lancet (2005) 3.85
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ (2002) 3.70
The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (2009) 3.67
Changes in Canadian heroin supply coinciding with the Australian heroin shortage. Addiction (2006) 3.65
Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct J (2006) 3.49
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis (2008) 3.38
Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr (2006) 3.38
Rationale for evaluating North America's first medically supervised safer-injecting facility. Lancet Infect Dis (2004) 3.20
Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ (2003) 3.19
Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet (2011) 3.14
Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis (2010) 3.12
The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Int J Drug Policy (2008) 3.05
Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS (2007) 3.04
Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology (2002) 2.99
Does ratification of human-rights treaties have effects on population health? Lancet (2009) 2.93
Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog (2007) 2.81
Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA (2008) 2.77
Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS (2002) 2.74
Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr (2005) 2.74
Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction (2010) 2.65
Displacement of Canada's largest public illicit drug market in response to a police crackdown. CMAJ (2004) 2.63
Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ (2004) 2.62
A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis (2006) 2.61
Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis (2011) 2.55
Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend (2006) 2.53
Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. CMAJ (2009) 2.51
When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis (2005) 2.48
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis (2005) 2.42
Knowledge to action: the development of training strategies. Healthc Policy (2008) 2.40
The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS (2007) 2.39
The impact of a police presence on access to needle exchange programs. J Acquir Immune Defic Syndr (2003) 2.37
Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend (2006) 2.33
CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 2.32
Hepatitis C virus reinfection in injection drug users. Hepatology (2006) 2.25
Binge drug use independently predicts HIV seroconversion among injection drug users: implications for public health strategies. Subst Use Misuse (2006) 2.22
A review of barriers and facilitators of HIV treatment among injection drug users. AIDS (2008) 2.21
Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure. CMAJ (2003) 2.18
Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS (2008) 2.14
The future of the regional training centres: planning for sustainability. Healthc Policy (2008) 2.14
Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir Ther (2004) 2.14